Business
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
- THRIVE-2 exceeded its enrollment target due to patient demand; 188 patients enrolled with approximately 40% from US sites - - THRIVE topline readout in
About this update from Viridian Therapeutics, Inc.
[{"type":"text","content":"\n- THRIVE-2 exceeded its enrollment target due to patient demand; 188 patients enrolled with approximately 40% from US sites -\n\n\n- THRIVE topline readout in patients with active TED on track for September 2024 -\n\n\n- THRIVE-2 topline readout on track for year-end 2024 -\n\n\n WALTHAM, Mass.--(BUSINESS WIRE)--\nViridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that enrollment is complete in THRIVE-2, its phase 3 clinical trial for VRDN-001 in patients with chronic TED.\n\n\nTHRIVE-2 enrolled 188 patients globally and exceeded the enrollment target of 159 patients due to patient demand. Approximately 40% of the enrolled patients were from US sites. Topline data from THRIVE-2 is on track for readout by year-end 2024. Previously, Viridian announced that THRIVE, its phase 3 clinical trial for VRDN-001 in patients with active TED, completed and exceeded enrollment in March 2024 with approximately 50% of patients enrolled from US sites. Topline data for THRIVE is on track for readout in September 2024.\n\n\n“We are very pleased with our overall clinical trial enrollment for the VRDN-001 trials,” said Steve Mahoney, Viridian’s President and Chief Executive Officer. “THRIVE and THRIVE-2 have now each exceeded their enrollment targets and enrolled substantial patient numbers in the US due to patient demand. We look forward to our topline data readout for THRIVE in September and for THRIVE-2 at the end of this year. We are also on track to initiate two subcutaneous VRDN-003 phase 3 clinical trials, REVEAL-1 and REVEAL-2, in August as planned.”\n\n\nAbout VRDN-001\n\n\nViridian’s lead product candidate, VRDN-001, is an intravenously (IV) delivered monoclonal antibody that acts as a full antagonist of the insulin-like growth factor-1 receptor (IGF-1R). IGF-1R is a clinically and commercially validated target for thyroid eye disease (TED) that had US revenues of approximately $1.8 billion in 2023. VRDN-001 has the potential to improve patient experience with a differentiated dosing regimen that features a shorter infusion time and fewer infusions compared to the currently approved and marketed IGF-1R inhibitor.\n\n\nViridian is evaluating VRDN-001 in two global phase 3 clinical trials, THRIVE and THRIV...